SYNAPTIKX
"SYNAPTIKX" is a word mark owned by SPOC Proteomics Inc., filed at the USPTO on September 4, 2025. It is in its opposition period and covers classes 9 and 42.
- Status
- Opposition period
- Since October 27, 2026
- Filed
- September 4, 2025
- Registered
- Not yet
- Expires
- Not recorded
- Application no.
- 99374819
- Registration no.
- Not yet
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Word mark
- 2 classes
Who owns SYNAPTIKX
The owner and representative on file with the office.
Owner
SPOC Proteomics Inc.
Scottsdale, United States
What the mark covers
The products and services SYNAPTIKX is filed for, grouped by Nice class.
Plates, glass slides or chips having multi-well arrays that can be used in chemical analysis, biological analysis or patterning for scientific, laboratory or medical research use; Sensor chips for scientific use
Drug discovery services; Pharmaceutical products development; Pharmaceutical research services; Pharmaceutical product evaluation; Pharmaceutical drug development services; Pharmaceutical research and development; Development of pharmaceutical preparations and medicines; Technical research in the field of pharmaceutical studies; Research and development services of new pharmaceutical products; Research and development in the pharmaceutical and biotechnology fields; Research and development services in the field of pharmaceutical preparations; Pharmaceutical research in the field of therapeutic discovery and development; Testing of pharmaceuticals; Laboratory research services relating to pharmaceuticals; Research on the subject of pharmaceuticals; Laboratory research in the field of pharmaceuticals; Development of pharmaceuticals for cell and gene therapies; Testing of pharmaceuticals for cell and gene therapies; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuff; Providing medical research information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Conducting early evaluations in the field of new pharmaceuticals; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Laboratory services for the production of pharmaceuticals in the nature of testing of pharmaceuticals; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development services in the field of antibodies; Medical research; Medical research services; Medical research laboratory services; Medical research in the field of oncology; Medical research in the field of pathology; Medical research in the field of infectious diseases; Medical research services in the field of cancer; Medical research in the field of rare diseases; Medical research laboratory services in the field of oncology; Research and development services in the field of medical preparations; Scientific research for medical purposes in the area of cancerous diseases; Providing information about medical research in the field of therapeutic discovery and development; Medical and scientific research in the field of cancer treatment and diagnosis; Technology research in the field of therapeutic discovery and development; Medical research in the field of therapeutic discovery and development; Research and development in the field of therapeutic discovery and development; Scientific research for medical purposes in the field of therapeutic discovery and development; Medical and scientific research in the field of therapeutic discovery and development; Medical and scientific research information in the field of therapeutic discovery and development; Laboratory services for biomanufacturing; Laboratory services for biomanufacturing of antibodies, peptides, and proteins for therapeutic evaluation; Biological research; Biological research and analysis; Biological research laboratory services; Biological research in the field of therapeutic discovery and development; Research in the field of synthetic biology; Biomedical research services; Biomedical research in the field of therapeutic discovery and development; Biotechnology research; Research and development in the field of biotechnology; Research and development services in the field of biotechnology; Biotechnology research in the field of therapeutic discovery and development
What has happened so far
Steps recorded by the USPTO, newest first.
- Opposition instituted no. 999999
- Extension of time to oppose received
- Official gazette publication confirmation e-mailed
- Published for opposition
- Notification of notice of publication e-mailed
- Approved for pub - principal register
- Notification of examiners amendment e-mailed
- Examiner's amendment entered
- Examiners amendment e-mailed
- Examiners amendment -written
7 earlier steps on the official record.
Oppositions and cancellations
Proceedings recorded against this mark by the USPTO. Reported as recorded, not legal advice.
About SYNAPTIKX
Who owns the trademark "SYNAPTIKX"?
The USPTO trademark "SYNAPTIKX" (application 99374819) is owned by SPOC Proteomics Inc.
What is the status of "SYNAPTIKX"?
Its status at the USPTO is: opposition period.
Get this data via the API
Everything on this page comes from the Signa API. Pull SYNAPTIKX and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019d2b22-b5a2-74fa-995d-af717b5d964a
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019d2b22-b5a2-74fa-995d-af717b5d964a",
"object": "trademark",
"mark_text": "SYNAPTIKX",
"status": {
"primary": "pending",
"stage": "pending_opposition"
},
"office_code": "US",
"application_number": "99374819",
"filing_date": "2025-09-04",
"nice_classes": [
9,
42
],
"owners": [
{
"name": "SPOC Proteomics Inc.",
"entity_id": null
}
]
}